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Benefit from chemotherapy treatment in breast cancer patients is determined by the molecular make-up of the tumour. In a
retrospective analysis, we determined the molecular subtypes of breast cancer originally defined by expression microarrays by
immunohistochemistry in tumours of patients who took part in a randomised study of adjuvant high-dose chemotherapy in breast
cancer. In addition, the topoisomerase IIa (TOP2A) amplification status was determined by fluorescence in situ hybridisation and
chromogenic in situ hybridisation. 411 of the 753 tumours (55%) were classified as luminal-like, 137 (18%) as basal-like and 205 (27%)
as human epithelial receptor type 2 (HER2) amplified. The basal-like tumours were defined as having no expression of ER and HER2;
98 of them did express epidermal growth factor receptor and/or cytokeratin 5/6. The luminal-like tumours had a significantly better
recurrence free and overall survival than the other two groups. From the 194 HER2-positive tumours, 47 (24%) were shown to
harbour an amplification of TOP2A. Patients with an HER2-amplified tumour randomised to the high-dose therapy arm did worse
than those in the conventional treatment arm, possibly caused by the lower cumulative anthracycline dose in the high-dose arm. The
tumours with a TOP2A amplification contributed hardly to this difference, suggesting that TOP2A amplification is not the cause of the
steep dose–response curve for anthracyclines in breast cancer. Possibly, the difference of the cumulative dose of only 25% between
the treatment arms was insufficient to yield a survival difference.
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The development of breast cancer is associated with a number of
genetic alterations involving the inactivation of tumour suppressor
genes and the activation of oncogenes. A dominant mechanism
leading to oncogene activation is the amplification of specific
genomic regions. Human epithelial receptor type 2 (HER2) (also
known as c-erb-B2) is frequently amplified in breast cancer and its
overexpression is associated with poor clinical outcome (Slamon
et al, 1987; Press et al, 1997). Amplification of HER2 can be
detected in about 15–30% of invasive breast cancers and these
carcinomas are often characterised by poor histologic grade, high
numbers of proliferating cells, DNA aneuploidy and the lack of
expression of oestrogen and progesterone receptors (Ross and
Fletcher, 1998). In addition, HER2 status has been suggested to
alter the chemosensitivity of cancer cells: HER2 overexpressing
cells have been reported to be relatively resistant to endocrine
therapy and marked differences may exist between HER2-positive
and -negative tumours concerning their response to alkylating
agents and to anthracyclines (Muss et al, 1994).
The HER2 amplicon is located on chromosome 17q12–21 that
harbours other biologically interesting genes such as topoisome-
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srase IIa (TOP2A), which encodes for an important enzyme in DNA
replication and in cell cycle progression. It catalyses the ATP-
dependent transport of one DNA double helix through another by
the transient introduction of a DNA double-strand break (Wang,
2002). This protein is also the target enzyme for anthracyclines,
which are among the most effective chemotherapeutic agents in
breast cancer. It has been suggested that amplification of TOP2A
and not overexpression of HER2 may, in fact, be the predictive
marker for response to anthracyclines (Coon et al, 2002; Di Leo
et al, 2002). This notion has been strengthened by a subgroup
analysis of the BCIRG-006 study, suggesting that the combination
of trastuzumab/doxorubicin is only superior to trastuzumab/
docetaxel in tumours harbouring an amplification of TOP2A (Press
et al, 2005).
Gene expression profiling has identified several subtypes of
invasive breast carcinomas associated with different clinical
outcomes (Sorlie et al, 2001; Sorlie et al, 2003). Perou et al
(2000) and Sorlie et al (2003) were able to distinguish different
groups of breast cancer based on differences in gene expression:
one group was called erb-B2-like and is characterised by HER2
overexpression, there were several subgroups called luminal A, B
and normal-like that all show expression of the oestrogen receptor
(ER) but no HER2 amplification, and one called the ‘basal-like’,
which does not express HER2 or hormone receptors but
cytokeratin 5/6 (CK5/6) and/or epidermal growth factor receptor
(EGFR). It was suggested that patients with basal-like tumours
would have a very poor prognosis. Obviously, neither trastuzumab
nor endocrine treatments are effective in this group. Additional
studies using immunohistochemistry (IHC) have identified a
pattern of four antibodies that is able to distinguish these
subgroups in archival paraffin-embedded tissue (van de Rijn
et al, 2002).
Recently, the large Dutch National Study investigating the effect
of high-dose alkylating chemotherapy in high-risk breast cancer
was published (Rodenhuis et al, 2003). This study concluded that a
benefit of high-dose chemotherapy is confined to patients
with HER2-negative tumours, whereas HER2-positive tumours
responded better to conventional, anthracycline-based chemo-
therapy. These results were subsequently confirmed in additional
analyses with a longer median follow-up (87 months) (Rodenhuis
et al, 2006).
In tumours of patients participating in this study, we retro-
spectively analysed the potential differences in prognosis or
treatment effect in the molecular subtypes of breast cancer
as defined by IHC. We also investigated whether amplification
status of TOP2A is correlated with specific benefit from conven-
tional-dose anthracycline-based chemotherapy compared to high-
dose alkylating chemotherapy in patients with HER2-positive
tumours.
MATERIALS AND METHODS
Patients
A total of 885 breast cancer patients were enroled into a
multicentre phase III trial. This study investigated the benefit of
high-dose adjuvant chemotherapy in patients with four or more
axillary lymph node metastases. The design of the study has been
described previously (Rodenhuis et al, 2003). Briefly, patients were
included when they were younger than 56 years of age, had
undergone surgery for their primary breast cancer and had at least
four tumour-positive axillary lymph nodes but no distant
metastases.
Patients were randomised to either five courses of anthracycline-
based conventional-dose chemotherapy or to the high-dose group,
where the fifth course of conventional-dose chemotherapy was
replaced by one course of high-dose chemotherapy (cyclophopha-
mide, thiotepa and carboplatin) followed by autologous peripheral
blood progenitor-cell transplantation.
Of 753 of the 885 patients, paraffin blocks of the primary tumour
could be procured. All tumour specimens were reviewed.
Additional IHC and chromogenic in situ hybridisation (CISH) or
fluorescence in situ hybridisation (FISH) stainings were per-
formed.
Chromogenic in situ hybridisation
Chromogenic in situ hybridisation was performed using the Spot-
Light CISH Polymer Detection Kit (Zymed, San Francisco, CA,
USA). The HER2 DNA probe and the TOP2A Amplification probe
were also received from Zymed (San Francisco, CA, USA).
Experiments were performed according to the manufacturer’s
protocol, in brief as follows:
Paraffin-embedded tissue specimens were immersed in xylene
twice and then soaked in 100% ethanol for three times. Heat
pretreatment was performed in a microwave step by using Zymed’s
pretreatment solution, DNA retrieval was carried out by a pepsin
step at room temperature. The slides were dehydrated in graded
ethanol series and the probe was applied to the tissue specimen
and denatured by a 5min step at 951C. Slides were incubated at
371C and washed the next day. Immunodetection was performed
by DAB-chromogen. Before scoring, tissue specimens were
counterstained with hematoxylin.
Fluorescence in situ hybridisation
The TOP2A FISH pharmDxt Kit (DAKO, Glostrup, Denmark) was
used to determine amplification of TOP2A by FISH, according to
the manufacturer’s protocol. Briefly, the tissue specimens were
deparaffinised by baking and rehydrated by graded ethanol series.
The DNA target was retrieved by pepsin treatment, the probe was
applied to the specimen and both were co-denatured at 821C for
5min. Hybridisation took place at 451C over night. The tissue
specimens were washed the next day and were then dehydrated by
graded ethanol series. Fluorescence signals were counted and
TOP2A amplification was determined.
Immunohistochemistry
Microscopic slides containing 5-mm sections of the tumour
material were stained with antibodies, which are commercially
available. The ER was stained with a mouse monoclonal antibody
(clone 1D5þ6F11, NeoMarkers, Fremont, CA, USA) in a dilution
of 1:50 with an autoclave antigen retrieval in citrate buffer (pH
6.0). The CK5/6 antibody (clone D5/16 B4, DakoCytomation,
Glostrup, Denmark) was diluted 1:200. Antigen retrieval was in
the autoclave in citrate buffer (pH 6.0). The HER2 antibody (clone
3B5) (van de Vijver et al, 1988) was diluted 1:80000 with a 15-min
microwave antigen retrieval in citrate buffer. For staining the
EGFR, samples were treated with 0.1% Pronase E (Sigma-Aldrich,
St Louis, MO, USA) for 20min at room temperature and stained
with EGFR antibody (clone 111.6, NeoMarkers, Fremont, CA, USA)
in a dilution of 1:100. Detection was performed with Power-
Visionþ (ImmunoVision Technology, Brisbane, CA, USA) using
an HRP-conjugated second antibody.
Scoring
Samples were scored as ER positive by IHC, when at least 10% of
the tumour cells showed staining of the ER in the nuclei.
Cytokeratin 5/6 and EGFR were reported as positive if membrane
staining for EGFR and any membrane or cytoplasmic staining for
CK5/6 could be observed. A sample was considered to be HER2
positive when either a strong membrane staining (3þ) could be
observed by IHC or CISH revealed amplification of HER2 in
samples with weak (1þ or 2þ) membrane staining at IHC.
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least 30 tumour cells were evaluated. According to the manufac-
turer’s instructions, tumours with an average of less than five spots
per nucleus were considered to be HER2 non-amplified, samples
with an average of at least or more than five spots per nucleus were
considered to be HER2 amplified. The same scoring system was
used for defining TOP2A gene amplification.
For tumour material examined by FISH, at least 40 nuclei were
evaluated and tumours were considered to be amplified for HER2
or TOP2A, respectively, when a probe/centromer ratio higher than
or equal to two was observed. Samples with a ratio of smaller than
two were scored as not amplified and a ratio p0.5 was defined as
deletion.
During the course of our study, CISH emerged as an equivalent
alternative to FISH. Therefore, cases tested in the early phase of the
study were analysed by FISH, whereas samples tested in the later
phase of the study were assessed by CISH.
Statistical analysis
The association of (a) the amplification of TOP2A and (b) the
molecular subtypes of breast cancer with recurrence-free and
overall survival was analysed using the Kaplan–Meier technique
and log-rank tests to compare different groups with each other and
Cox-proportional hazard analysis for calculating hazard ratios
with 95% confidence intervals. Recurrence-free survival time was
calculated from date of randomisation until time of first event,
either recurrence of disease or death. Overall survival was defined
as time from randomisation until date of death or date of last
follow-up. The interaction of the parameters with treatment in
relation to outcome was depicted by means of a Forest-plot. In this
Forest-plot, the closed squares represent the point estimate of the
effect of high-dose chemotherapy (HD) vs conventional-dose
therapy (CONV) within that particular subgroup (with the size
of the square corresponding to its variance) and the lines
correspond to the 99% confidence interval of that effect. The
open figure at the bottom shows the overall effect of high-dose
chemotherapy vs CONV for this particular cohort of patients.
RESULTS
Between August 1993 and July 1999, 885 patients from 10 Dutch
hospitals were randomised between conventional-dose and high-
dose chemotherapy. Patients in the conventional arm received five
courses of anthracycline-based chemotherapy, whereas patients in
the high-dose arm received only four courses (Rodenhuis et al,
2003). We identified the molecular subtypes of breast cancer in 753
out of 885 patients by the combination of four immunohisto-
chemical markers (HER2-positive, luminal ER-positive and basal-
like CK5/6, and/or EGFR-positive breast cancer). The TOP2A
amplification status was assessed by CISH or FISH in the subgroup
of HER2-positive tumours (n¼194).
Patient and tumour characteristics: HER2-positive patients
with TOP2A data available
A total of 194 patients were analysed in this subgroup of HER2-
positive tumours. Ninety-four of these had been randomly treated
in the high-dose chemotherapy arm, 100 had been treated in the
conventional-dose chemotherapy arm. The two groups had similar
clinical characteristics (Table 1).
Patient and tumour characteristics: breast cancer subtype
analyses
The analysis of the four different subtypes of breast cancer was
performed on samples of 753 patients. A total 376 patients were
randomised to the high-dose chemotherapy arm and 377 patients
to the conventional-dose treatment arm. There was no difference
in clinical characteristics between the patients from whom
paraffin-embedded material was available and those from whom
samples were not available (Table 2).
Correlation of HER2 and TOP2A amplification by CISH
and FISH
We performed FISH experiments to detect TOP2A amplification on
all samples that were scored as HER2 1þ,2þ or 3þ by IHC and
from which paraffin-embedded tumour material was available. As
TOP2A gene amplification is extremely rare (and not detected at all
in some studies), we did not test immunohistochemically HER2-
negative tumours for TOP2A gene amplification.
Of the 211 samples, an interpretable FISH-TOP2A result was
obtained in 203 cases. On a further 16 samples, we performed
CISH-TOP2A staining and 10 of these were appropriate for
scoring. In total, we could establish the amplification status of
TOP2A in 213 cases. In total, TOP2A data are available from 194
HER2-positive and 19 HER2-negative tumours. Forty-seven of the
samples (22%) showed co-amplification of TOP2A and HER2,
whereas the majority of the cases were positive for HER2, but had
no amplification of TOP2A (69%). Among the cases without
TOP2A gene amplification (but with HER2 gene amplification),
there were nine cases with loss of one TOP2A allele. The results are
summarised in Table 3.
Table 1 Clinical characteristics TOP2A samples
No of patients
without
amplification
of TOP2A
N¼147 (%)
No of patients
with amplification
of TOP2A
N¼47 (%)
Total
N¼194 (%)
Treatment
Conventional arm 75 (51%) 25 (53%) 100 (52%)
High-dose arm 72 (49%) 22 (47%) 94 (48%)
Age
o40 years 46 (31%) 19 (40%) 65 (34%)
40–50 years 70 (48%) 18 (38%) 88 (45%)
50+ years 31 (21%) 10 (21%) 41 (21%)
Menopausal status at time of randomisation
Premenopausal 123 (84%) 41 (87%) 164 (85%)
Postmenopausal 13 (9%) 5 (11%) 18 (9%)
Uncertain 11 (7%) 1 (2%) 12 (6%)
Type of surgery
Mastectomy 112 (76%) 37 (79%) 149 (77%)
Breast conserving 35 (24%) 10 (21%) 45 (23%)
Tumour classification
T1 33 (22%) 6 (13%) 39 (20%)
T2 88 (60%) 32 (68%) 120 (62%)
T3 26 (18%) 9 (19%) 35 (18%)
Number of positive lymph nodes
4–9 96 (65%) 28 (60%) 124 (64%)
X10 51 (35%) 19 (40%) 70 (36%)
Grade
I 7 (5%) 3 (6%) 10 (5%)
II 37 (25%) 16 (34%) 53 (27%)
III 99 (67%) 26 (55%) 125 (64%)
Not determined 4 (3%) 2 (4%) 6 (3%)
TOP2A¼topoisomerase IIa.
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It has been suggested that sensitivity to anthracycline-based
chemotherapy is associated with amplification and overexpression
of TOP2A (Coon et al, 2002; Di Leo et al, 2002). We therefore
examined the presence of a (recurrence-free) survival advantage
for patients with TOP2A-amplified tumours in the conventional-
dose arm over those in the high-dose arm that contained a 20%
lower cumulative dose of anthracyclines.
A total of 194 patients, from whom information on TOP2A gene
amplification, chemotherapy treatment and clinical follow-up were
available, had tumours with HER2 gene amplification. We
separated the patients with and without amplification of the
TOP2A gene in two groups and generated Kaplan–Meier survival
curves with a median follow-up of 87 months. For HER2-positive
patients with TOP2A amplification, no survival differences
between high-dose and conventional chemotherapy seems to be
present (Figure 1). The curves do not suggest an apparent
interaction between or confounding effect of TOP2A on the
relation between treatment and survival.
Also the subgroups analysis of HER2-positive/TOP2A-negative
vs HER2-positive/TOP2A-positive samples did not show an effect
of TOP2A amplification (data not shown). Additionally, we
analysed the impact of TOP2A amplification status on treatment-
related survival in the group of HER2 positive, ER-negative
patients separately to exclude any indirect endocrine effect. The
results are not different from the results of the analyses of the
whole set of cases (data not shown), although it should be kept in
mind that these subsets are relatively small and therefore
confidence intervals are wide.
Determination of the different subtypes of invasive breast
cancer by IHC
Several subtypes of breast cancer have been identified recently and
have been correlated with clinical outcome (Sorlie et al, 2001, 2003;
van de Rijn et al, 2002). These results have been translated to
classical IHC (Nielsen et al, 2004). We therefore used the
combination of four antibodies to identify these subtypes within
our patient cohort and correlated these results with survival after
high-dose or conventional chemotherapy.
We first stained all cases from which paraffin-embedded
material was available with antibodies against HER2, ER, CK5/6
and EGFR. Twenty-five percent of the samples were positive for
HER2, 70% were positive for ER, 12% of the cases showed strong
expression of CK5/6 and 15% of the cases expressed EGFR. Table 4
summarises the frequencies of positive and negative staining of
these four markers. We also investigated the focal staining of CK5/
6. From 92 patients stained positive for CK5/6, 28 showed focal
staining p5%, 28 samples showed staining between 5 and 50% and
in 36 cases at least 50% of the tumour cells were positive for CK5/6.
Subsequently, we divided 753 samples into three breast cancer
subtypes according to the results obtained from the IHC and the
additional CISH staining. How the different molecular subtypes
were defined by IHC is shown in Table 5. A total of 205 cases (27%)
were assigned to the HER2-positive group and 411 samples (55%)
to the luminal, ER-positive group. Thirteen percent of the samples
showed expression of CK5/6 and/or EGFR and are therefore
termed basal-like. Five percent of the cases do not show expression
of the evaluated markers (Table 5). For analytic purposes, the
tumours are categorised as part of the basal-like group. In the
HER2-positive group, 15% of the cases also expressed CK5/6
or EGFR. In the ER-positive samples, 6% showed expression of
CK5/6 or EGFR. Most of the tumours with amplification of
TOP2A show neither expression of CK5/6 nor EGFR, only in two
TOP2A-amplified samples expression of CK5/6 or EGFR could be
detected.
Association of the breast cancer subtypes with patient’s
survival
It has been reported that the basal type of breast cancer is
correlated with poor clinical outcome (van de Rijn et al, 2002). We
therefore used the patient cohort of 753 patients that could be
grouped into three subtypes of invasive breast cancer and studied
the recurrence-free and overall survival of these groups. Kaplan–
Meier survival curves of the ER expressing, the HER2 expressing
and the basal-like subgroup are shown in Figure 2A. Patients with
luminal ER-expressing tumours showed better survival compared
to those in the other two groups (5-year overall survival 81%, 95%
confidence interval 78–85%). If one compares the basal-like
tumours and the HER2-amplified ones, a similar recurrence-free
Table 2 Clinical characteristics all samples
No of patients
without available
samples
N¼132
No of patients
with formalin-fixed
samples
N¼753
Total study
population
N¼885
Treatment
Conventional arm 66 (50%) 377 (50%) 443 (50%)
High-dose arm 66 (50%) 376 (50%) 442 (50%)
Age
o40 years 30 (23%) 195 (26%) 225 (25%)
40–50 years 74 (56%) 391 (52%) 465 (53%)
50+ years 28 (21%) 167 (22%) 195 (22%)
Menopausal status at time of randomisation
Premenopausal 103 (78%) 630 (84%) 733 (83%)
Postmenopausal 25 (19%) 100 (13%) 125 (14%)
Uncertain 4 (3%) 23 (3%) 27 (3%)
Type of surgery
Mastectomy 113 (86%) 577 (77%) 690 (78%)
Breast conserving 19 (14%) 176 (23%) 195 (22%)
Tumour classification
T1 — ( ) 2 (0%) 2 (0%)
T2 30 (23%) 171 (23%) 201 (23%)
T3 78 (59%) 460 (61%) 538 (61%)
Unknown 24 (18%) 120 (16%) 144 (16%)
Number of positive lymph nodes
4–9 83 (63%) 485 (64%) 568 (64%)
X10 49 (37%) 268 (36%) 317 (36%)
Grade
I 19 (14%) 135 (18%) 154 (17%)
II 29 (22%) 263 (35%) 292 (33%)
III 35 (27%) 331 (44%) 366 (41%)
Not determined 49 (37%) 24 (3%) 73 (8%)
Table 3 Comparison: TOP2A amplification/HER2 overexpression
TOP2A amplification
HER2 positivity Positive Negative Total
Positive 47 (22%) 147 (69%) 194
Negative 2 (1%) 17 (8%) 19
Total 49 164 213
HER2¼human epithelial receptor type 2; TOP2A¼topoisomerase IIa. Overview of
HER2/neu positivity and the amplification of topoisomerase IIa in 213 patients. HER2
positivity is defined as overexpression (3+ score by IHC) or HER2 gene amplification
detected by CISH (performed for IHC 1+ and 2+ cases).
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sand overall-survival probability is observed (5-year overall survival
rates 56 and 60%, 95% confidence intervals 48–65 and 54–67%,
respectively). Importantly, the patients with HER2-positive tu-
mours did not receive adjuvant trastuzumab in this study.
For the three different subgroups, we also determined the
hazard ratios of recurrence-free survival after conventional-dose
or high-dose chemotherapy, respectively (Figure 2B). Oestrogen
receptor-positive tumours and tumours in the basal-like/negative
Overall survival
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Figure 1 Recurrence-free and overall survival among the HER2-positive patients. (A and D) all patients with TOP2A data; (B and E) 147 patients
without amplification of TOP2A; (C and F) 47 patients with amplification of TOP2A. Tumours were considered to be TOP2A amplified, when there was a
probe/centromer ratio X2 by FISH or more than fish spots detected by CISH.
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whereas a trend is seen that tumours with HER2 amplification
might benefit more from conventional chemotherapy. This finding
is in line with previously published results (Rodenhuis et al, 2003;
Rodenhuis et al, 2006)
DISCUSSION
In this study, the pathology and survival data of a large cohort of
patients with high-risk primary breast cancer were reanalysed
(Rodenhuis et al, 2003; Rodenhuis et al, 2006) We retrospectively
Table 4 Frequency of the immunostainings defining the basal-like
subtype of invasive breast carcinomas
Antigen Interpretable staining Positive staining Negative staining
HER2/neu 826 205 (25%) 621 (75%)
ER 823 577 (70%) 246 (30%)
CK5/6 762 92 (12%) 670 (88%)
EGFR 763 116 (15%) 647 (85%)
CK5/6¼cytokeratin 5/6; EGFR¼epidermal growth factor receptor; ER¼estrogen
receptorHER2¼human epithelial receptor type 2.
Table 5 Frequency of the subtypes of 753 invasive breast cancers
defined by immunohistochemistry
Group HER2/neu ER CK5/6 and/or EGFR Frequency
HER2 Positive Any Any 205 (27%)
ER (luminal) Negative Positive Negative 411 (55%)
Basal-like Negative Negative One or both positive 98 (13%)
Negative Negative Negative Negative 39 (5%)
CK5/6¼cytokeratin 5/6; EGFR¼epidermal growth factor receptor; ER¼estrogen
receptor; HER2¼human epithelial receptor type 2.
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Figure 2 (A) Recurrence-free and overall survival among the HER2-expressing, ER-expressing and the basal-like subtype of invasive breast cancer. (B)
Forrest plot – Correlation of the recurrence free survival in these subgroups with response to conventional anthracycline-based or alkylating high-dose
chemotherapy, respectively.
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based on IHC with treatment outcome and we investigated a
possible influence of the anthracycline dose on treatment effect for
tumours with a TOP2A amplification.
Several studies have suggested that anthracyclines such as
doxorubicin have a steep dose–response curve in HER2-positive
breast cancer (Muss et al, 1994), but a supposed sensitivity to
anthracyclines has not been confirmed invariably (Paik et al, 1998;
Thor et al, 1998; Vincent-Salomon et al, 2000). As the
anthracyclines target the enzyme TOP2A, it has been suggested
that co-amplification of TOP2A could be the actual mechanism
underlying the relationship between HER2 overexpression and the
efficacy of optimally dosed anthracycline-based chemotherapy.
This concept is also supported by the finding that cells with
amplification of both HER2 and TOP2A are highly sensitive to
anthracyclines in vitro (Jarvinen et al, 2000). In the clinical setting,
only a few studies have been published regarding the predictive
value of TOP2A amplification in breast cancer patients (Coon et al,
2002; Di Leo et al, 2002). A recent study by Knoop et al, 2005
investigated TOP2A changes in 773 tumour samples. They found
that amplification (and possibly deletion) of the TOP2A gene seem
to be predictive for the effect of adjuvant epirubicin containing
therapy. If it could be unambiguously shown that the difference in
sensitivity to anthracyclines between HER2-positive and HER2-
negative tumours is explained by the amplification of the TOP2A
gene, clinical decision making in adjuvant therapy should, in part,
be guided by assessing the TOP2A gene amplification status. As
TOP2A gene amplification is only found in HER2-amplified
tumours, a sensible testing algorithm would be to test only
HER2-amplified cases for TOP2A status.
In the study presented here, we determined the amplification
status of TOP2A in all HER2-positive tumours of the patient cohort
of the Dutch National trial of high-dose chemotherapy (Rodenhuis
et al, 2003). Among the tumours with HER2 gene amplification,
only 22% showed co-amplification of the TOP2A gene and 1% of
the cases showed deletion of the TOP2A gene. These data are in
agreement with the hypothesis that amplification or deletion of the
TOP2A gene is associated with HER2 gene amplification as a result
of the colocalisation of both genes on the chromosomal region
17q12–q21. It has been suggested previously that, after initial
amplification of HER2, additional chromosomal rearrangement
events lead to either telomeric high level amplifications or
interstitial deletions, which may encompass the TOP2A gene
(Jarvinen et al, 1999).
We subsequently determined the survival-rates for the HER2-
positive tumours of this patient cohort after conventional-dose and
high-dose chemotherapy dependent on the TOP2A gene amplifica-
tion status of the tumours. There was no relative difference in
recurrence-free or overall survival of TOP2A gene amplified vs
non-amplified tumours depending on the arm of the study
(Figure 1). Petit et al, 2001 have shown that FE100C was more
effective than FE50C in the neoadjuvant setting in patients with
HER2-positive disease, whereas for HER2-negative disease no
difference between these two schedules could be observed.
Although this and other studies suggest that the efficacy of
anthracyclines in HER2-positive tumours is dose dependent in the
adjuvant (Muss et al, 1994) and neoadjuvant setting (Petit et al,
2001), it is possible that the difference of the cumulative dose of
only 25% between the treatment arms was insufficient to yield a
survival difference. Nevertheless, TOP2A gene amplification does
not appear to be the main reason that HER2-positive tumours did
worse after high-dose alkylating chemotherapy.
Based on gene expression profiling studies (Sorlie et al, 2001;
Sorlie et al, 2003), invasive breast cancer can be divided into
several subtypes: the basal-like, characterised by the expression of
the CK5/6 and or EGFR, the luminal ER-positive groups, and a
HER2 overexpressing group. This classification has been translated
to classical IHC (Nielsen et al, 2004) and a combination of four
immunohistochemical markers (ER, HER2, CK5/6 and EGFR) can
be used to distinguish between these subgroups. The basal-like
tumours are defined as being negative for HER2 and ER. For
technical reasons, it is important to base classification not only on
negative markers, as technical failure could not be detected in such
cases. Therefore, we used the expression of CK5/6 and EGFR to
identify basal-like tumours. Other studies also describe a relation-
ship between the expression of c-KIT and CK17 and the basal-like
subtype of breast cancer, but these markers are not that frequently
positive as CK5/6 (Nielsen et al, 2004). The definition of the
molecular subgroups based on IHC is given in Table 3. The basal-
like subtype has been reported to be associated with very poor
prognosis. Clearly, there may also be a difference in response to
specific chemotherapeutic regimens for each of these subgroups,
which would establish a predictive value in addition to the
prognostic one. Within the set of patients analysed, we identified
13% of the cases as belonging to the basal-like subgroup based on
the expression of CK5/6 and/of EGFR. This result confirms that of
Nielsen et al (2004), who found that 15% of 663 invasive breast
carcinomas were basal-like based on IHC and expression of either
CK5/6 or HER1.
In accordance with previously published data (Rodenhuis et al,
2003), patients with a HER2-negative tumour appeared to benefit
from high-dose chemotherapy. On the contrary, patients with
HER2-positive tumours actually did better with conventional-dose
anthracycline-based chemotherapy. The recurrence-free and over-
all survivals of the basal-like/negative group are comparable to
those of the group of HER2 overexpressing tumours (Figure 2).
Both groups, however, have a poor prognosis in comparison with
the luminal, ER overexpressing subgroup. In a recent report,
Nielsen et al (2004) have characterised the basal-like subtype by
IHC and have studied the clinical outcome. The expression of CK5/
6 or EGFR (termed HER1 in his study) was used as the hallmark of
the basal-like subtype of invasive breast cancer and was indeed
associated with poor survival. Similarly, van de Rijn et al (2002)
could correlate the expression of CK5/6 in tissue arrays with poor
prognosis). As the expression of CK5/6 is usually very focal within
a tumour, the interpretation of tissue arrays may underestimate
the percentage of CK5/6 expressing tumours. We therefore used
whole tissue sections to determine the expression of CK5/6 and
EGFR. In our data set, from 92 patients stained positive for CK5/6,
about one-third showed focal staining p5%, one-third showed
staining between 5 and 50% and in about one-third of the cases at
least 50% of the tumour cells were positive for CK5/6.
Of the 98 patients in the basal-like group, 45 co-expressed CK5/6
and EGFR, and 28 basal-like tumours expressed EGFR but not
CK5/6. Epidermal growth factor receptor belongs to the family of
tyrosine-receptor kinases and is a target for small molecule
inhibitors such as erlotinib and gefitinib and for therapeutic
antibodies such as cetuximab (Esteva, 2004). As these drugs are
target-specific, their combination with other targeted agents or
with chemotherapy could, in theory, improve outcome when EGFR
overexpression is present in a basal-like tumour.
In conclusion, by employing IHC, breast cancer can conveni-
ently be divided in at least three molecular subtypes, which have a
different prognosis and which require different treatment.
Although we could confirm that the TOP2A gene is amplified in
a proportion of tumours harbouring an HER2 amplification, this
abnormality does not appear to be responsible for the lack of
efficacy of high-dose alkylating chemotherapy in this patient
group. The existence of a (cumulative) dose–response effect of
epirubicin in these patients could, however, not be excluded on the
basis of our data.
Patients with tumours that were either HER2 positive or
negative for the investigated markers had a significantly worse
relapse-free survival than tumours of the luminal type. If adjuvant
trastuzumab had been used in this study, the results in the HER2-
positive tumours could have been expected to be far better. Thus,
TOP2A amplification and molecular subtypes in breast cancer
J Hannemann et al
1340
British Journal of Cancer (2006) 95(10), 1334–1341 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sthe basal-like breast cancer subtype remains the least favourable
one, for which at present conventional chemotherapy rather than
treatment with targeted agents remains the primary systemic
treatment modality.
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